Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

FDA approves NovoSeven RT for Glanzmann's thrombasthenia

July 8, 2014

Xenetic Biosciences reports safety data from ongoing phase II study of ErepoXen

July 2, 2014

FDA grants small business waver of PDUFA fee for Rockwell's Triferic

July 2, 2014

EMA's CHMP recommends new approval for Eliquis

June 30, 2014

Boehringer Ingelheim's idarucizumab receives FDA breakthrough therapy designation

June 27, 2014

Bayer patent describes potential hemophilia treatments

June 27, 2014

Bayer HealthCare and Dimension Therapeutics to develop novel gene therapy for hemophilia A

June 25, 2014

Caplacizumab achieves clinical proof-of-concept in phase II TITAN study

June 18, 2014

Takeda to withdraw Omontys NDA and terminate license with Affymax

June 18, 2014

FDA removes clinical hold on imetelstat myelofibrosis trial

June 16, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 27, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 27, 2025
New drugs with the same old resistance tricks?
BioWorld
According to the World Health Organization (WHO), multidrug-resistant pathogens caused over 1.27 million deaths worldwide in 2020. And figures are rising, with...
OS Therapies heading to FDA with positive osteosarcoma data
BioWorld
With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies Inc. anticipates a regulatory filing...
Vilastobart set apart? Xilio phase II combo performs in CRC
BioWorld
“The [colorectal cancer field is moving, and thankfully it’s moving quickly,” said Marwan Fakih, gastrointestinal specialist at City of Hope, speaking about...